New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
07:32 EDTDNDNDendreon reports Q4 EPS (26c), consensus (56c)
Reports Q4 revenue $85.5M, consensus $82.88M. The company expects to reduce cost of goods sold to below 50% of net product revenue in the beginning of 3Q13. Expects to begin to see net benefits associated with the restructuring initiatives to begin to appear in financial results as early as 1H13, with full benefits realized in Q313. Says actively evaluating partnering strategies for European expansion; continuing to enroll patients in the sipuleucel-T European Union open-label study; expect a mid-2013 regulatory decision in Europe.
News For DNDN From The Last 14 Days
Check below for free stories on DNDN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
16:15 EDTDNDNDendreon names W. Thomas Amick as president, CEO
Dendreon announced that its board has appointed W. Thomas Amick as president and CEO, effective immediately. Amick has also been appointed to the company’s board of directors. Amick succeeds John H. Johnson, who previously announced his plans to step down as president and CEO for personal reasons. Johnson will work with Amick through August 15 to ensure a smooth transition. Most recently from 2010 to 2012, Amick served as chairman and CEO of Discovery Labs, a specialty biotechnology company.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use